These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37435091)

  • 21. Multiple Autoimmune Syndromes Including Acute Disseminated Encephalomyelitis, Myasthenia Gravis, and Thyroiditis Following Messenger Ribonucleic Acid-Based COVID-19 Vaccination: A Case Report.
    Poli K; Poli S; Ziemann U
    Front Neurol; 2022; 13():913515. PubMed ID: 35711270
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association between COVID-19 vaccination and myasthenia gravis: A population-based, nested case-control study.
    Arbel A; Bishara H; Barnett-Griness O; Cohen S; Najjar-Debbiny R; Gronich N; Auriel E; Saliba W
    Eur J Neurol; 2023 Dec; 30(12):3868-3876. PubMed ID: 37552795
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of SARS-CoV-2 immunization on COVID-19 disease course in people with myasthenia gravis.
    Bakirtzis C; Boziki MK; Karakasi MV; Moysiadis T; Grigoriadis N
    Muscle Nerve; 2023 May; 67(5):412-416. PubMed ID: 36814101
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
    Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Clinical Course of New-Onset Ocular Myasthenia Gravis Caused by Pfizer-BioNTech COVID-19 Vaccine.
    Su WY; Lu CJ
    Acta Neurol Taiwan; 2023 Dec; 32(4)():218-222. PubMed ID: 37723915
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New-onset pediatric nephrotic syndrome following Pfizer-BioNTech SARS-CoV-2 vaccination: a case report and literature review.
    Nakazawa E; Uchimura T; Hirai Y; Togashi H; Oyama Y; Inaba A; Shiga K; Ito S
    CEN Case Rep; 2022 May; 11(2):242-246. PubMed ID: 34782983
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between history of SARS-CoV-2 infection and severe systemic adverse events after mRNA COVID-19 vaccination among U.S. adults.
    Tompkins LK; Baggs J; Myers TR; Gee JM; Marquez PL; Kennedy SB; Peake D; Dua D; Hause AM; Strid P; Abara W; Rossetti R; Shimabukuro TT; Shay DK
    Vaccine; 2022 Dec; 40(52):7653-7659. PubMed ID: 36372665
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity, safety and clinical outcomes of the SARS-CoV-2 BNT162b2 vaccine in adolescents with type 1 diabetes.
    Emeksiz HC; Hepokur MN; Şahin SE; Şirvan BN; Çiçek B; Önder A; Yıldız M; Aksakal DK; Bideci A; Ovalı HF; İşman F
    Front Pediatr; 2023; 11():1191706. PubMed ID: 37435175
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
    Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL
    Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Myasthenia Gravis Triggered by a COVID-19 Infection: A Case Report and Literature Review.
    Mincă A; Mincă DI; Calinoiu AL; Gheorghiță V; Popescu CC; Rusu A; Cristea AM; Mincă DG
    Cureus; 2024 May; 16(5):e59538. PubMed ID: 38827012
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study.
    Lopez Bernal J; Andrews N; Gower C; Robertson C; Stowe J; Tessier E; Simmons R; Cottrell S; Roberts R; O'Doherty M; Brown K; Cameron C; Stockton D; McMenamin J; Ramsay M
    BMJ; 2021 May; 373():n1088. PubMed ID: 33985964
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [COVID-19 infections and effectiveness of the vaccination among healthcare workers].
    Rojkovich B; Németh D; Dinya E; Nagy E; Török E; Lázár I; Perduk A; Géher P; Nagy G
    Orv Hetil; 2023 Feb; 164(5):163-171. PubMed ID: 36739547
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tolerability of COVID-19 Infection and Messenger RNA Vaccination Among Patients With a History of Kawasaki Disease.
    Beckley M; Olson AK; Portman MA
    JAMA Netw Open; 2022 Aug; 5(8):e2226236. PubMed ID: 35960521
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
    Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
    Front Immunol; 2022; 13():863554. PubMed ID: 35711445
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early-Onset Myasthenia Gravis Following COVID-19 Vaccination.
    Lee MA; Lee C; Park JH; Lee JH
    J Korean Med Sci; 2022 Mar; 37(10):e50. PubMed ID: 35289135
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Case of COVID-19 Vaccine Causing a Myasthenia Gravis Crisis.
    Tagliaferri AR; Narvaneni S; Azzam MH; Grist W
    Cureus; 2021 Jun; 13(6):e15581. PubMed ID: 34277203
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Myasthenia gravis at the crossroad of COVID-19: focus on immunological and respiratory interplay.
    Galassi G; Marchioni A
    Acta Neurol Belg; 2021 Jun; 121(3):633-642. PubMed ID: 33811309
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence of Allergic Reactions After Pfizer-BioNTech COVID-19 Vaccination Among Adults With High Allergy Risk.
    Shavit R; Maoz-Segal R; Iancovici-Kidon M; Offengenden I; Haj Yahia S; Machnes Maayan D; Lifshitz-Tunitsky Y; Niznik S; Frizinsky S; Deutch M; Elbaz E; Genaim H; Rahav G; Levy I; Belkin A; Regev-Yochay G; Afek A; Agmon-Levin N
    JAMA Netw Open; 2021 Aug; 4(8):e2122255. PubMed ID: 34463744
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of COVID-19 in AChR Myasthenia Gravis and the Safety of Vaccines: Data from an Italian Cohort.
    Lupica A; Di Stefano V; Iacono S; Pignolo A; Quartana M; Gagliardo A; Fierro B; Brighina F
    Neurol Int; 2022 Apr; 14(2):406-416. PubMed ID: 35645352
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Comparative Analyses of IgA Antibody Response of Non-COVID-19 Infected People Over 60 Years Old Following CoronaVac and Pfizer-BioNTech COVID-19 Vaccination].
    Yürüker Ö; Yetkin O; Güvenir M
    Mikrobiyol Bul; 2023 Apr; 57(2):330-333. PubMed ID: 37067217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.